Medicare Officials Signal No Payment Changes On Anemia DrugsThe Associated Press: Medicare Declines Payment Changes On Anemia Drugs
Medicare officials signaled Wednesday that they will not change a payment policy for biotech drugs made by Amgen and Johnson & Johnson when they are used to treat anemia in kidney disease patients, despite data suggesting heart risks for those patients. The Centers for Medicare and Medicaid posted a memo online saying it will not issue a national rule on how doctors should use the drugs when treating patients in the government's Medicare plan, which covers 47 million seniors. The agency said it will take comments on this proposal before finalizing it by June 17 (3/16). This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.